Market Overview

LifeTech Capital Raises Echo Therapeutics PT To $6 (ECTE)


LifeTech Capital raised its Echo Therapeutics (OTC: ECTE) price target to $6 from $4.50 and maintained Echo Therapeutics Strong Speculative Buy rating in a research report published today.

In the report, LifeTech Capital states, "Echo Therapeutics Symphony™ transdermal continuous glucose monitor (tCGM) system is a unique needle-free, wireless system which we believe is set to begin a pivotal clinical trial in ICU/Critical Care patients during 2011 (following a final pilot trial). We believe this puts Echo Therapeutics ahead of the curve with respect to tougher FDA standards for hospital use."

Shares of Echo Therapeutics closed Friday at $4.25, down 9.96% from Thursday's market close.

Posted-In: LifeTech CapitalAnalyst Color Price Target Analyst Ratings


Related Articles

View Comments and Join the Discussion!

Morgan Keegan Maintains Outperform on Healthcare Realty Trust (HR)

Avnet Names Rick Hamada CEO, Effective July 4